Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs everolimus in previously treated advanced/metastatic clear-cell renal cell carcinoma
jRCT2080221968Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overall survival. Started Nov 2012; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2080221968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221968.